NASDAQ:ACAD - ACADIA Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$17.67 -0.33 (-1.83 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$17.67
Today's Range$17.59 - $18.25
52-Week Range$14.51 - $41.20
Volume1.66 million shs
Average Volume2.75 million shs
Market Capitalization$2.25 billion
P/E Ratio-7.49
Dividend YieldN/A
Beta3.37

About ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACAD
CUSIPN/A
Phone858-558-2871

Debt

Debt-to-Equity RatioN/A
Current Ratio7.38
Quick Ratio7.26

Price-To-Earnings

Trailing P/E Ratio-7.49
Forward P/E Ratio-10.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$124.90 million
Price / Sales17.66
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book6.54

Profitability

EPS (Most Recent Fiscal Year)($2.36)
Net Income$-289,400,000.00
Net Margins-161.44%
Return on Equity-71.47%
Return on Assets-63.74%

Miscellaneous

Employees425
Outstanding Shares124,830,000

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Friday, May, 4th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.12. The biopharmaceutical company earned $48.90 million during the quarter, compared to analyst estimates of $47.06 million. ACADIA Pharmaceuticals had a negative return on equity of 71.47% and a negative net margin of 161.44%. The business's revenue for the quarter was up 219.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.72) EPS. View ACADIA Pharmaceuticals' Earnings History.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for ACADIA Pharmaceuticals.

What price target have analysts set for ACAD?

12 equities research analysts have issued 1-year target prices for ACADIA Pharmaceuticals' shares. Their forecasts range from $45.00 to $61.00. On average, they expect ACADIA Pharmaceuticals' stock price to reach $51.2727 in the next twelve months. View Analyst Ratings for ACADIA Pharmaceuticals.

What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (5/9/2018)
  • 2. HC Wainwright analysts commented, "HARMONY Study Initiation: Killing Multiple" Birds With One Stone? Reit Buy and $60 PT Initiation of the Ph3 HARMONY study is one step forward with our bull thesis. With the initiation of HARMONY study in dementia-related psychosis (DRP) and discontinuation of SEREN study in AD agitation, we applaud what we view as a smart move by Acadia of pursuing a broader indication for pimavanserin, and more importantly, doing so with a solid clinical plan moving forward. At first glance, the seemingly bold move into DRP from ADP may appear over-ambitious (killing multiple" birds with one stone). However, we note that a psychosis focus/approach may prove to be a smart play from both the commercial point of view and also from the mechanistic perspective. The blessing from the FDA with a Breakthrough Designation further elevates our sanguine outlook for the program. We highlight the significant upside coming with the DRP expansion as the target market is potentially bigger than ADP alone (if we assume ADP comprises 70% of the DRP)." (10/5/2017)

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest in April. As of April 13th, there was short interest totalling 13,203,966 shares, an increase of 16.7% from the March 30th total of 11,319,177 shares. Based on an average trading volume of 5,224,064 shares, the short-interest ratio is currently 2.5 days. Currently, 10.7% of the shares of the stock are sold short.

Who are some of ACADIA Pharmaceuticals' key competitors?

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen R. Davis, Pres, CEO & Director (Age 57)
  • Mr. Todd S. Young, Exec. VP, CFO & Principal Accounting Officer (Age 46)
  • Mr. Glenn F. Baity, Exec. VP, Gen. Counsel and Sec. (Age 48)
  • Dr. Srdjan R. Stankovic M.D., M.S.P.H., Head of R&D and Exec. VP (Age 61)
  • Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations

Has ACADIA Pharmaceuticals been receiving favorable news coverage?

News articles about ACAD stock have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 0.22 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.40 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.33%), OppenheimerFunds Inc. (3.48%), Franklin Resources Inc. (1.74%), JPMorgan Chase & Co. (1.54%), Palo Alto Investors LP (1.32%) and Millennium Management LLC (0.53%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Edmund Harrigan, Glenn Baity, Laura Brege and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Which major investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., OppenheimerFunds Inc., Stanley Laman Group Ltd., Eventide Asset Management LLC, Prudential Financial Inc., BlackRock Inc., SG Americas Securities LLC and JPMorgan Chase & Co.. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Glenn Baity and Laura Brege. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Which major investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, Frontier Capital Management Co. LLC, The Manufacturers Life Insurance Company , First Washington CORP, Handelsbanken Fonder AB, Handelsbanken Fonder AB and Massachusetts Financial Services Co. MA. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Daniel B Soland and Edmund Harrigan. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $17.67.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $2.25 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. ACADIA Pharmaceuticals employs 425 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]


MarketBeat Community Rating for ACADIA Pharmaceuticals (ACAD)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  526 (Vote Outperform)
Underperform Votes:  238 (Vote Underperform)
Total Votes:  764
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for ACADIA Pharmaceuticals in the last 12 months. Their average twelve-month price target is $51.2727, suggesting that the stock has a possible upside of 190.17%. The high price target for ACAD is $61.00 and the low price target for ACAD is $45.00. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.832.83
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.2727$51.2727$51.2727$49.4167
Price Target Upside: 190.17% upside189.02% upside73.04% upside66.78% upside

ACADIA Pharmaceuticals (NASDAQ:ACAD) Consensus Price Target History

Price Target History for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ:ACAD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018HC WainwrightReiterated RatingBuyMediumView Rating Details
4/10/2018JPMorgan ChaseSet Price TargetBuy$50.00HighView Rating Details
11/7/2017CowenReiterated RatingBuy$46.00N/AView Rating Details
10/12/2017Jefferies GroupReiterated RatingBuy$47.00N/AView Rating Details
10/9/2017Leerink SwannReiterated RatingMarket PerformN/AView Rating Details
10/6/2017Goldman SachsReiterated RatingNeutral$45.00N/AView Rating Details
10/5/2017Piper Jaffray CompaniesReiterated RatingBuy$54.00 ➝ $61.00N/AView Rating Details
10/5/2017Bank of AmericaBoost Price TargetBuy ➝ Positive$40.00 ➝ $46.00N/AView Rating Details
10/5/2017JMP SecuritiesBoost Price TargetOutperform$47.00 ➝ $50.00N/AView Rating Details
10/2/2017Ladenburg ThalmannReiterated RatingBuy$48.00 ➝ $50.00LowView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$49.00LowView Rating Details
5/22/2017Rodman & RenshawReiterated RatingBuy$60.00LowView Rating Details
10/19/2016Roth CapitalReiterated RatingNeutral$25.00N/AView Rating Details
8/5/2016AegisDowngradeBuy ➝ Hold$54.00 ➝ $41.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earnings History and Estimates Chart

Earnings by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earnings Estimates

2018 EPS Consensus Estimate: ($1.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.55)($0.55)($0.55)
Q2 20181($0.50)($0.50)($0.50)
Q3 20181($0.45)($0.45)($0.45)
Q4 20181($0.41)($0.41)($0.41)

ACADIA Pharmaceuticals (NASDAQ ACAD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.46)N/AView Earnings Details
5/4/20183/31/2018($0.56)($0.44)$47.06 million$48.90 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.58)($0.55)$45.30 million$43.56 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.63)($0.53)$32.03 million$35.58 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.72)($0.55)$20.02 million$30.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.7310)($0.72)$15.17 million$15.30 millionViewListenView Earnings Details
2/28/2017Q416($0.65)($0.65)$9.05 million$12.00 millionViewListenView Earnings Details
11/7/2016Q316($0.56)($0.61)$2.90 million$5.30 millionViewListenView Earnings Details
8/4/2016Q216($0.49)($0.63)$0.71 million$0.97 millionViewListenView Earnings Details
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details
5/7/2015Q115($0.25)($0.40)$0.09 millionViewListenView Earnings Details
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details
11/10/2014Q3($0.12)($0.25)$0.02 millionViewListenView Earnings Details
8/5/2014Q2($0.17)($0.22)$0.10 million$0.03 millionViewListenView Earnings Details
5/6/2014Q1($0.13)($0.19)$0.50 million$0.03 millionViewListenView Earnings Details
2/27/2014Q4($0.14)($0.13)$0.30 million$0.04 millionViewListenView Earnings Details
11/6/2013Q3 2013($0.12)($0.12)$0.25 million$0.24 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.4170 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.08)($0.11)ViewN/AView Earnings Details
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details
8/8/2012Q2 2012($0.12)($0.10)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.11)($0.12)ViewN/AView Earnings Details
3/6/2012Q4 2011($0.10)($0.10)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.10)($0.10)ViewN/AView Earnings Details
8/10/2011Q2 2011($0.15)($0.10)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.11)($0.12)ViewN/AView Earnings Details
3/10/2011Q4 2010$0.69$0.74ViewN/AView Earnings Details
11/9/2010Q3 2010($0.17)($0.11)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.16)($0.11)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.17)($0.14)ViewN/AView Earnings Details
3/9/2010Q4 2009($0.19)($0.23)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.27)($0.23)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.34)($0.34)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.36)($0.40)ViewN/AView Earnings Details
3/9/2009Q4 2008($0.38)($0.38)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.43)($0.36)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.46)($0.49)ViewN/AView Earnings Details
5/5/2008Q1 2008($0.46)($0.44)ViewN/AView Earnings Details
3/5/2008Q4 2007($0.46)($0.46)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ACADIA Pharmaceuticals (NASDAQ:ACAD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ACADIA Pharmaceuticals (NASDAQ ACAD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 97.19%
Insider Trading History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ ACAD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2018Daniel B SolandDirectorBuy7,000$23.91$167,370.002,000View SEC Filing  
1/29/2018Glenn BaityEVPSell36,558$32.39$1,184,113.6283,734View SEC Filing  
1/2/2018Glenn BaityEVPSell74,321$30.14$2,240,034.94View SEC Filing  
1/2/2018Laura BregeDirectorSell25,000$30.06$751,500.0015,000View SEC Filing  
10/5/2017Glenn BaityEVPSell37,500$40.91$1,534,125.00View SEC Filing  
8/30/2017Glenn BaityEVPSell26,507$34.87$924,299.0994,163View SEC Filing  
8/9/2017Glenn BaityEVPSell14,322$34.88$499,551.3678,578View SEC Filing  
7/20/2017Glenn BaityEVPSell38,097$30.00$1,142,910.00109,253View SEC Filing  
6/22/2017Glenn BaityEVPSell1,903$30.00$57,090.0083,059View SEC Filing  
2/16/2017Terrence O. MooreEVPSell157,540$39.77$6,265,365.80View SEC Filing  
12/27/2016Glenn BaityEVPSell9,800$30.46$298,508.0081,363View SEC Filing  
12/20/2016Glenn BaityEVPSell10,000$30.00$300,000.00View SEC Filing  
8/16/2016Edmund HarriganDirectorBuy1,000$32.97$32,970.001,000View SEC Filing  
8/10/2016Bros. Advisors Lp BakerDirectorBuy1,303,030$33.00$42,999,990.00View SEC Filing  
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.0066,978View SEC Filing  
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.0066,978View SEC Filing  
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.4169,824View SEC Filing  
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.0036,127View SEC Filing  
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.0023,848View SEC Filing  
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.0047,788View SEC Filing  
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.6515,775View SEC Filing  
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.408,500View SEC Filing  
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.0031,585View SEC Filing  
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ACADIA Pharmaceuticals (NASDAQ ACAD) News Headlines

Source:
DateHeadline
Acadia Pharmaceuticals (ACAD) Rating Reiterated by HC WainwrightAcadia Pharmaceuticals (ACAD) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - May 19 at 10:56 AM
Better Buy: Acadia Pharmaceuticals vs. BiogenBetter Buy: Acadia Pharmaceuticals vs. Biogen
www.fool.com - May 18 at 2:40 PM
Acadia Pharmaceuticals (ACAD) Rating Increased to Buy at BidaskClubAcadia Pharmaceuticals (ACAD) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - May 16 at 4:50 PM
Edited Transcript of ACAD earnings conference call or presentation 4-May-18 12:30pm GMTEdited Transcript of ACAD earnings conference call or presentation 4-May-18 12:30pm GMT
finance.yahoo.com - May 15 at 5:24 PM
Interesting ACAD Put And Call Options For June 29thInteresting ACAD Put And Call Options For June 29th
www.nasdaq.com - May 10 at 5:21 PM
Acadia Pharmaceuticals (ACAD) Cut to Hold at Zacks Investment ResearchAcadia Pharmaceuticals (ACAD) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:09 PM
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
finance.yahoo.com - May 8 at 5:07 PM
Acadia: Damn The Torpedoes, Full Speed AheadAcadia: Damn The Torpedoes, Full Speed Ahead
seekingalpha.com - May 8 at 8:47 AM
Acadia Pharmaceuticals (ACAD) Receives Average Rating of "Buy" from BrokeragesAcadia Pharmaceuticals (ACAD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 7 at 1:48 PM
Today’s Research Reports on Stocks to Watch: ACADIA Pharmaceuticals and Portola PharmaceuticalsToday’s Research Reports on Stocks to Watch: ACADIA Pharmaceuticals and Portola Pharmaceuticals
finance.yahoo.com - May 7 at 8:45 AM
Blog Exposure - Alnylam Pharma Attained Alignment with FDA on Pivotal Study Design for Lumasiran for Treatment of Primary Hyperoxaluria Type 1Blog Exposure - Alnylam Pharma Attained Alignment with FDA on Pivotal Study Design for Lumasiran for Treatment of Primary Hyperoxaluria Type 1
finance.yahoo.com - May 7 at 8:45 AM
Acadia Pharmaceuticals (ACAD) Expected to Announce Quarterly Sales of $58.99 MillionAcadia Pharmaceuticals (ACAD) Expected to Announce Quarterly Sales of $58.99 Million
www.americanbankingnews.com - May 6 at 4:12 AM
ACADIA Pharmaceuticals (ACAD) CEO Steve Davis on Q1 2018 Results - Earnings Call TranscriptACADIA Pharmaceuticals' (ACAD) CEO Steve Davis on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 5:00 PM
Why Acadia Pharmaceuticals Jumped 11% Higher TodayWhy Acadia Pharmaceuticals Jumped 11% Higher Today
finance.yahoo.com - May 4 at 5:00 PM
Acadia Pharmaceuticals (ACAD) Announces Quarterly  Earnings ResultsAcadia Pharmaceuticals (ACAD) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 4 at 4:36 PM
Acadia Pharmaceuticals (ACAD) Expected to Announce Earnings of -$0.56 Per ShareAcadia Pharmaceuticals (ACAD) Expected to Announce Earnings of -$0.56 Per Share
www.americanbankingnews.com - May 4 at 11:30 AM
Earnings Reaction History: ACADIA Pharmaceuticals Inc, 66.7% Follow-Through Indicator, 9.2% SensitiveEarnings Reaction History: ACADIA Pharmaceuticals Inc, 66.7% Follow-Through Indicator, 9.2% Sensitive
www.nasdaq.com - May 4 at 8:46 AM
Form 8-K ACADIA PHARMACEUTICALS For: May 04Form 8-K ACADIA PHARMACEUTICALS For: May 04
www.streetinsider.com - May 4 at 8:46 AM
Acadia Pharma Q1 Nuplazid sales $48.9M; shares up 5% premarketAcadia Pharma Q1 Nuplazid sales $48.9M; shares up 5% premarket
seekingalpha.com - May 4 at 8:46 AM
ACADIA Posts Narrower than Expected Loss in Q1, Sales BeatACADIA Posts Narrower than Expected Loss in Q1, Sales Beat
www.zacks.com - May 4 at 8:46 AM
BRIEF-Acadia Pharmaceuticals Q1 Loss Per Share $0.44BRIEF-Acadia Pharmaceuticals Q1 Loss Per Share $0.44
www.reuters.com - May 4 at 8:46 AM
ACADIA Pharmaceuticals Reports First Quarter 2018 Financial ResultsACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 4 at 8:46 AM
Acadia: 1Q Earnings SnapshotAcadia: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:46 AM
ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor RelationsACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
finance.yahoo.com - May 2 at 5:09 PM
Acadia Pharmaceuticals (ACAD) Raised to "Buy" at Zacks Investment ResearchAcadia Pharmaceuticals (ACAD) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 1 at 6:06 PM
ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018
finance.yahoo.com - May 1 at 4:54 PM
Will ACADIA (ACAD) Disappoint Investors This Earnings Season?Will ACADIA (ACAD) Disappoint Investors This Earnings Season?
finance.yahoo.com - May 1 at 4:54 PM
BRIEF-Acadia Pharmaceuticals Says CEO Stephen Daviss FY 2017 Total Compensation Was $15.2 MlnBRIEF-Acadia Pharmaceuticals Says CEO Stephen Davis's FY 2017 Total Compensation Was $15.2 Mln
www.reuters.com - May 1 at 8:53 AM
Acadia Pharmaceuticals (ACAD) to Release Quarterly Earnings on MondayAcadia Pharmaceuticals (ACAD) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 7:10 AM
Acadia stands behind risk/benefit profile of Nuplazid; shares up 4% premarketAcadia stands behind risk/benefit profile of Nuplazid; shares up 4% premarket
seekingalpha.com - April 27 at 9:08 AM
RSI Alert: Acadia Pharmaceuticals (ACAD) Now OversoldRSI Alert: Acadia Pharmaceuticals (ACAD) Now Oversold
www.nasdaq.com - April 26 at 8:41 AM
Here’s What Just Happened With AcadiaHere’s What Just Happened With Acadia
finance.yahoo.com - April 26 at 8:41 AM
Today’s Research Reports on Stocks to Watch: Dare Bioscience and ACADIAToday’s Research Reports on Stocks to Watch: Dare Bioscience and ACADIA
finance.yahoo.com - April 26 at 8:41 AM
Acadia Pharmaceuticals (ACAD) Short Interest Up 16.7% in AprilAcadia Pharmaceuticals (ACAD) Short Interest Up 16.7% in April
www.americanbankingnews.com - April 26 at 2:22 AM
FDA says reviewing Acadias Parkinsons medication, shares fallFDA says reviewing Acadia's Parkinson's medication, shares fall
finance.yahoo.com - April 25 at 5:08 PM
This Explains Why Acadia Pharmaceuticals Is Selling Off TodayThis Explains Why Acadia Pharmaceuticals Is Selling Off Today
finance.yahoo.com - April 25 at 5:08 PM
PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s DiseasePMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease
www.businesswire.com - April 23 at 4:54 PM
Zacks Investment Research Upgrades Acadia Pharmaceuticals (ACAD) to "Buy"Zacks Investment Research Upgrades Acadia Pharmaceuticals (ACAD) to "Buy"
www.americanbankingnews.com - April 19 at 11:33 AM
Acadia Pharmaceuticals (ACAD) Upgraded to Hold by BidaskClubAcadia Pharmaceuticals (ACAD) Upgraded to Hold by BidaskClub
www.americanbankingnews.com - April 19 at 11:11 AM
$46.52 Million in Sales Expected for Acadia Pharmaceuticals (ACAD) This Quarter$46.52 Million in Sales Expected for Acadia Pharmaceuticals (ACAD) This Quarter
www.americanbankingnews.com - April 19 at 4:23 AM
 Analysts Anticipate Acadia Pharmaceuticals (ACAD) Will Post Earnings of -$0.56 Per Share Analysts Anticipate Acadia Pharmaceuticals (ACAD) Will Post Earnings of -$0.56 Per Share
www.americanbankingnews.com - April 17 at 8:00 AM
Acadia Pharmaceuticals (ACAD) Upgraded by BidaskClub to "Hold"Acadia Pharmaceuticals (ACAD) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 16 at 7:35 PM
Acadia Pharmaceuticals (ACAD) Receives Consensus Rating of "Hold" from AnalystsAcadia Pharmaceuticals (ACAD) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 12 at 1:41 PM
Acadia Pharmaceuticals (ACAD) "Buy" Rating Reaffirmed at HC WainwrightAcadia Pharmaceuticals' (ACAD) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 11 at 11:23 PM
Acadia Pharma up 6% on FDA OK on risk disclosures for NuplazidAcadia Pharma up 6% on FDA OK on risk disclosures for Nuplazid
seekingalpha.com - April 11 at 5:02 PM
Acadia Pharmaceuticals (ACAD) "Outperform" Rating Reiterated at CowenAcadia Pharmaceuticals' (ACAD) "Outperform" Rating Reiterated at Cowen
www.americanbankingnews.com - April 11 at 4:31 PM
Acadia Pharmaceuticals (ACAD) Raised to Sell at ValuEngineAcadia Pharmaceuticals (ACAD) Raised to Sell at ValuEngine
www.americanbankingnews.com - April 11 at 3:58 PM
Acadia Pharmaceuticals (ACAD) Cut to Sell at BidaskClubAcadia Pharmaceuticals (ACAD) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 11:30 AM
Dont Try to Catch This Falling KnifeDon't Try to Catch This Falling Knife
finance.yahoo.com - April 11 at 9:13 AM
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD): Does The Earnings Decline Make It An Underperformer?ACADIA Pharmaceuticals Inc (NASDAQ:ACAD): Does The Earnings Decline Make It An Underperformer?
finance.yahoo.com - April 11 at 9:13 AM

SEC Filings

ACADIA Pharmaceuticals (NASDAQ:ACAD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ACADIA Pharmaceuticals (NASDAQ:ACAD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ACADIA Pharmaceuticals (NASDAQ ACAD) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.